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Abstract 
ATM is an important signalling molecule in the DNA damage response (DDR). ATM 
loss of function can produce a synthetic lethal phenotype in combination with tumour-
associated mutations in FA/BRCA pathway components. In this study, we took an 
siRNA screening strategy to identify other tumour suppressors which when inhibited 
similarly sensitized cells to ATM inhibition. In this manner, we determined that PTEN 
and ATM were synthetically lethal when jointly inhibited. PTEN-deficient cells 
exhibited elevated levels of reactive oxygen species, increased endogenous DNA 
damage and constitutive ATM activation. ATM inhibition caused catastrophic DNA 
damage, mitotic cell cycle arrest and apoptosis specifically in PTEN-deficient cells in 
comparison to wild-type cells. Antioxidants abrogated the increase in DNA damage 
and ATM activation in PTEN-deficient cells, suggesting a requirement for oxidative 
DNA damage in the mechanism of cell death. Lastly, the ATM inhibitor 
KU-60019 was specifically toxic to PTEN mutant cancer cells in tumour xenografts 
and reversible by re-introduction of wild-type PTEN. Together our results offer a 
mechanistic rationale for clinical evaluation of ATM inhibitors in PTEN-deficient 
tumours. 
 
Abbreviations: PTEN, phosphatase and tensin homolog deleted on chromosome 
10; ATM, ataxia telangiectasia mutated; DSB, double strand break; ROS, reactive 
oxygen species. 
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Introduction 
Ataxia telangiectasia mutated (ATM) is the primary kinase, which responds to DNA 
double strand breaks (DSB) (1). Therapeutic inhibition of ATM has been shown to 
sensitize cells to ionising radiation and DNA damaging chemotherapeutic agents 
(2,3) suggesting that it may have a role in combination therapy for cancer. 
Increasingly, however, it has been found that DNA damage response targeted 
therapies, for example PARP inhibitors, may also exhibit single agent activity in the 
context of loss of specific tumour suppressors such as BRCA1 or BRCA2 (4) ATM 
inhibitors have a potential role as single agents in the context of loss of components 
of the FA/BRCA pathway (5). An siRNA library screen identified synthetic lethality 
between loss of ATM function and loss of various components of the FA/BRCA 
pathway that have been reported in human cancers. Combined loss of ATM and the 
FA/BRCA pathway resulted in the accumulation of lethal DNA damage and cell 
death. In the current study we ask if loss of ATM could be synthetically lethal with 
other known human tumour suppressors, thereby indicating other single agent 
targets for ATM inhibitors. We use an siRNA library designed to individually target 
known human tumour suppressors to screen against an isogenic ATM wild-type and 
deficient cell line system in order to identify synthetic lethal interactions. We 
consequently identify synthetic lethality between PTEN and ATM and demonstrate a 
role for ATM in promoting the survival of PTEN-deficient cells through the signalling 
of oxidative DNA damage. 
 
Materials and Methods 
Cell lines 
All cell lines were sourced from the American Tissue Culture Collection (ATCC). 
HCT116 cells lacking wild-type PTEN have been described previously and were 
licensed from Georgetown University (6). The PC3-PTEN inducible cell lines (7) and 
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ATM deficient human fibroblasts and reconstituted cells have previously been 
described (8) (Supplementary Information and Supplementary Fig 1a). 
 
Cell cycle, Apoptosis and Mitotic chromosome analysis 
Cells were fixed in 70% ethanol, incubated with RNase A and propidium iodide (PI) 
and analysed with a FACSCalibur (Becton Dickinson) using CellQuest Pro software. 
For phospho-histone H3 analysis, cells were incubated with anti-phospho-histone H3 
antibody (Upstate Biotechnology). Apoptotic assays were performed using the 
luminescence Caspase-Glo® 3/7 assay from Promega. To assess chromosome 
damage, cells were treated with colcemid (0.05μg/ml) (KaryoMAX, GibcoBRL) for 4 
hours. 
 
Western blotting analysis 
Cell pellets were lysed in 20 mM Tris (pH 8), 200 mM NaCl, 1 mM EDTA, 0.5% (v/v) 
NP-40, 10% (v/v) glycerol. For phospho-H2AX detection, histones were extracted 
overnight at 4oC in 0.2N HCL from protein pellets. Lysates and histone extracts were 
electrophoresed on NuPage pre-cast gels (Invitrogen), and immunoblotted with anti –
phospho-H2AX (Cell Signalling Technology); anti-PTEN (Santa Cruz); anti- phospho-
ATM ser1981 (Cell Signalling Technology); anti- phospho-CHK2 thr68 (Cell 
Signalling Technology) and anti- phospho-AKT ser473 (Cell Signalling Technology). 
As loading controls, anti- β-Actin (Sigma); anti- Vinculin (Cell Signalling Technology) 
and anti-Tubulin (Abcam) were used. This was followed by incubation with anti IgG-
HRP (Cell Signaling Technology) and chemiluminescent detection (ECL-PLUS; 
Amersham, UK). 
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Reactive Oxygen Species Detection 
Cells were incubated with 5μM CM-H2DCF-DA (Invitrogen) for 30 minutes followed 
by flow cytometry.  
 
Colony formation assays 
Cells were seeded at predetermined densities, 24 hours later treated with KU-55933 
(Calbiochem), which was replenished every 3-4 days. Where appropriate, cells were 
transfected with gene specific targeting siRNAs (Qiagen) using LipofectamineTM 
RNAiMAX (Invitrogen) and 48 hours later counted and seeded for colony formation 
assay. After 10 days, cells were washed with PBS, fixed in methanol, stained with 
crystal violet and colonies counted. The surviving fraction (SF) for a given 
dose/siRNA was calculated and dose-response curves plotted using GraphPad 
Prism™ 5 * p=<0.05 Students-t test. 
 
siRNA screening 
A customised siRNA library targeting 178 tumour suppressor genes or genes whose 
loss of function was associated with cancer (Supplementary Table 1) was developed 
using predesigned siRNA sequences (Qiagen). The library contained 3 independent 
siRNA sequences per gene and was provided in an arrayed format in 96 well plates. 
ATM deficient and ATM complemented cells were reverse transfected with the siRNA 
library (Qiagen) using Lipofectamine RNAiMax reagent (Life Technologies) 
(Supplementary Information). 
 
Xenograft study 
3 x 107 cells were implanted into male Fox Chase Severe Combined 
Immunodeficiency (SCID) mice (Charles River Laboratories, Oxford, UK). 
Administration of doxycycline was started when tumours reached 100mm3 in volume 
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and was performed every 48 hours up to removal of the animal from the experiment. 
48 hours after PTEN induction, animals were administered KU-60019 (100mg/kg) for 
5 consecutive days and measured until they reached a target 400mm3 volume. 
Measurements of tumour volume and body weight took place every 3 days using 
calipers (Supplementary Information). 
PTEN-deficient tumour cells are dependent on ATM signalling 
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Results  
ATM is a potential drug target for PTEN-deficient cells 
In order to identify potential synthetic lethality interactions with ATM loss we used a 
customised siRNA library targeting 178 tumour suppressor genes (Supplementary 
Table 1). The library was used to screen against ATM-deficient and ATM-
complemented fibroblasts (Supplementary Fig. 1A) (8). This isogenic cell line was 
found to be preferable to therapeutic ATM inhibition for the purpose of initial 
screening as there was less likely to be non-specific off-target interactions with the 
siRNA targets or the ATP-dependent reagents used for viability read-out. Robust Z-
scores were calculated for 3 independent siRNA per gene and an average value was 
then generated. The screen identified 9 genes that were synthetically lethal with loss 
of PTEN (Table 1). Each of these 9 genes demonstrated an average Robust Z-score 
≤ -2 (Fig. 1A.). Consistent with previous data, we found that components of the 
FA/BRCA pathway were synthetically lethal with ATM loss. In addition, CDKN2C and 
p53, genes involved in the G1/S checkpoint were synthetically lethal with ATM 
deficiency, indicating that they may play a compensatory role in maintaining cellular 
viability in the absence of ATM-mediated cell cycle check-pointing. Interestingly, the 
tumour suppressor PTEN was also synthetically lethal with ATM. Similar to ATM, 
PTEN had been reported to have a direct role in the DNA damage response (9-11) 
and Ioss of its function represented a potentially important drug target, as inactivating 
mutations are associated with incurable cancers such as advanced prostate cancer 
and glioblastoma (12). We therefore took PTEN forward into secondary validation as 
a synthetic lethal candidate. 
 
For validation of PTEN as a hit from the screen, we performed colony formation 
assays in the ATM isogenic cells. PTEN knock-down using 2 independent siRNAs, 
resulted in reduced survival of ATM deficient cells compared to ATM wild-type 
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corrected cells (fold difference of 48% and 40%) (Fig.1B). Next, we assessed the 
sensitivity of the HCT116 (6) and PC3 (7) isogenic cell line models (Supplementary 
Fig. 1.A-B) to loss of ATM function using either gene specific siRNA or the ATM 
inhibitor KU-55933 (2). Both the PTEN-deficient cell-lines demonstrated increased 
sensitivity to siRNA mediated knock-down of ATM (fold difference of 20% and 42%) 
(Fig. 1C) and increased sensitivity to the KU-55933 (fold change in IC50 of 16 and 8) 
compared to wild-type counterparts (Fig. 1D). PTEN null cells have constitutive 
activation of AKT. We therefore ensured that KU-55933 did not inhibit AKT, and the 
observed sensitivity in PTEN null cells was independent of AKT function 
(Supplementary Fig. 2). 
 
To confirm that the observed ATM inhibitor sensitivity in PTEN-deficient cells was not 
model specific, we tested a panel of cell-lines representing PTEN wild-type and deficient 
states in prostate cancer, glioblastoma, breast cancer and normal cells. In each case the 
PTEN-deficient cell line demonstrated increased sensitivity to the ATM inhibitor KU-
55933 compared to the PTEN wild-type cell line (Supplementary Fig. 1C), suggesting 
that this strategy may be of value as a treatment in more than one cancer type. In 
addition, advanced prostate cancers and glioblastomas are associated with PTEN loss 
(12) and are often treated with radiation hence ATM inhibitors may be particularly useful 
in these indications where they may have a dual role.  
 
PTEN-deficient cells have elevated levels of ROS, DNA damage and activation 
of ATM 
It has previously been reported that PTEN-deficient cells exhibit abnormal 
homologous recombination (HR) mediated DNA repair through loss of expression of 
RAD51 (9, 13). However this observation has not been consistent across cell line 
models (10-11) or in human tumour samples (14). Loss of RAD51 expression could 
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potentially have accounted for the synthetic lethal interaction between PTEN and 
ATM. However, we did not find any association between RAD51 expression or foci 
formation and PTEN expression in our isogenic cell line systems with or without DNA 
damage, suggesting that HR functions normally in both cell lines (Supplementary Fig. 
3A and Supplementary Fig. 3B). Moreover, both PTEN wild-type and deficient cells 
were sensitive to depletion of RAD51 by siRNA, the sensitivity being more 
pronounced in the deficient cells (Supplementary Fig. 3C). This further supports an 
alternative mechanism to loss of HR in PTEN deficient cells underlying the synthetic 
lethality with ATM inhibition. 
 
PTEN null mouse embryonic fibroblasts have been reported to exhibit increased 
oxidative DNA damage (15), we therefore asked if there were increased levels of 
oxidative damage in the PC3 and HCT116 isogenic models. We used a 
fluorescence-based assay to measure reactive oxygen species (ROS) and observed 
a shift in the fluorescence-intensity of 10±1% and 12±2% associated with PTEN-
deficiency in HCT116 and PC3 isogenic cell line models respectively (Fig. 2A). In 
addition there was a greater induction of ROS in PTEN-deficient compared to wild-
type cells in the presence of the KU-55933 with increases of 21±2% and 25±3% in 
HCT116 and PC3 respectively. This observation suggests that ATM inhibition may 
further enhance oxidative stress in PTEN null cells. Oxidative DNA lesions have been 
reported to result in DSBs with consequent induction of histone-H2AX 
phosphorylation (γ-H2AX), a marker of DSBs (16). Consistent with this, the PTEN-
deficient cell lines demonstrated increased baseline levels of γ-H2AX (Fig. 2B and 
Supplementary Fig. 3D). In addition, Western blot analysis demonstrated constitutive 
phosphorylation of ATM (a marker of activation) and its substrate Chk2, in PTEN-
deficient cells (Fig. 2B), consistent with an ATM-mediated response to DSBs.  
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To further investigate if the observed increase in γ-H2AX and ATM phosphorylation in 
PTEN-deficient cells was the result of increased oxidative damage, we pre-treated 
the PTEN-deficient cell line HCT116 KO22 with the antioxidants N-acetyl cysteine or 
beta-carotene. Following treatment with these agents, we observed reduced γ-H2AX 
expression and phospho-ATM indicating that oxidative DNA damage was the likely 
cause for the increase in DSBs (Fig. 2C). In summary these data suggest that PTEN-
deficient cells have high levels of oxidative stress, resulting in increased DNA 
damage and subsequent ATM activation. 
 
Next we asked if the observed increase in oxidative DNA damage in PTEN-deficient 
cells was required for ATM inhibitor sensitivity. We pre-treated the HCT116 PTEN-
deficient and wild-type isogenic cell lines with N-acetyl cysteine or beta-carotene and 
tested the sensitivity to the ATM inhibitor KU-55933 (Fig. 2D). Each of the 
antioxidants rescued KU-55933 sensitivity in the PTEN-deficient cell line, indicating 
that oxidative damage is required to sensitise PTEN-deficient cells to ATM inhibition. 
 
Acute inhibition of ATM in PTEN-deficient cells results in cell cycle arrest, 
chromosome aberrations and apoptosis 
To investigate how DNA damage following ATM inhibition resulted in a loss of cellular 
viability specifically in PTEN-deficient cells, we analysed the cell cycle profile of the 
cells with or without KU-55933 treatment. ATM inhibition resulted in a greater G2/M 
arrest in the HCT116 PTEN-deficient cells compared to wild-type cells (Fig. 3A). 
Furthermore, analysis of Histone H3 serine 10 phosphorylation (a measure of the 
mitotic cellular population) demonstrated that these cells were specifically arrested in 
mitosis (Fig. 3B). We then examined whether the accumulation of cells in M phase 
was associated with DNA damage. Chromosome spreads demonstrated an increase 
in aberrations, predominantly in the PTEN deficient cells, including radial 
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chromosomes following ATM inhibition, (Fig. 3C). This indicates that in PTEN-
deficient cells, ATM normally functions to prevent catastrophic DNA damage 
progressing into the M phase of the cell cycle. Furthermore, treatment with the ATM 
inhibitor resulted in increased caspase 3/7 activation specifically in the HCT116 
PTEN-deficient cell line (62%) compared to wild-type counterpart (8%) consistent 
with apoptotic cell death (Fig. 3D). 
 
In vivo efficacy of ATM inhibition in PTEN-deficient xenografts 
To investigate the in vivo efficacy of ATM specific inhibition in PTEN-deficient cells, 
we used the PC3 PTEN Tetracycline inducible cell line model in a subcutaneous 
xenograft setting. Firstly, we established that the Tetracycline derivative Doxycycline 
was efficient at inducing PTEN expression in vitro (Supplementary Fig. 4A) and in 
vivo (Supplementary Fig. 4B). Calliper measurements of tumour volumes showed 
that induction of PTEN using Doxycycline, led to a slowing of tumour growth from 72 
hours onwards (Supplementary Fig. 4C). Next, we investigated the selective toxicity 
of the ATM specific kinase inhibitor KU-60019 (17) as a single modality in the PC3-
PTEN inducible model. This inhibitor was chosen, as it is a potent ATM inhibitor and 
unlike KU-55933 is active in animal systems. Despite PTEN-deficient control tumours 
reaching a 4-fold increase in size before PTEN wild-type controls, KU-60019 treated 
PTEN-deficient tumours displayed a statistically significant slowing in growth (Fig. 
4A). This growth inhibition was especially evident at the start of the experiment (days 
5-12) just after KU-60019 was administered (day 1-5). There were no significant 
changes in the mean relative body weights of each treatment groups (Fig. 4B). 
Inducible PTEN expression in vivo was analysed in resected tumours by 
immunofluorescence (Supplementary Fig. 4D). 
 
Discussion 
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PTEN lost in a wide variety of human cancers (12), and its primary role as a tumour 
suppressor is through inhibition of the PI3/AKT pathway (18). However more 
recently, PTEN has been reported to maintain genomic integrity and confer 
resistance to ionising radiation and PARP inhibition (9-11,13), which is a nuclear 
function and independent from AKT regulation (19). In the current study we have 
reported a synthetic lethal interaction between loss of ATM and loss of PTEN. Loss 
of PTEN results in increased oxidative damage, which is required for the sensitization 
to ATM inhibition, as anti-oxidants can rescue PTEN-deficient cells from ATM- 
inhibitor-mediated cell death. Oxidative DNA lesions can result in stalled DNA 
replication forks and resultant DSBs (16) and activation of ATM (1). Hence loss of 
ATM function in PTEN-deficient cells may therefore result in a persistence of 
oxidative DNA lesions and inactivation of the G2M checkpoint, allowing cells with 
catastrophic DNA damage to enter the M phase of the cell cycle and undergo cell 
death. Importantly, ATM has been reported to function to prevent malignant 
progression of pre-malignant conditions through the signalling of oncogene-related 
DNA damage (20). Our data suggest that once a cell has become malignant through 
additional genetic abnormalities e.g. loss of PTEN, the cancer cell can then become 
dependent on ATM activation to maintain a level of DNA integrity required for 
survival. In summary, we have demonstrated that PTEN and ATM are synthetically 
lethal, and furthermore we have found a requirement for ATM in the maintenance of 
DNA integrity and cellular viability in the presence of increased oxidative damage 
secondary to PTEN deficiency. The selective sensitivity of PTEN-deficient tumours to 
ATM inhibition in vivo suggests that this may represent a novel approach to targeted 
cancer therapy in the clinic. 
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Figure Legends 
Figure 1: ATM is a potential drug target for PTEN-deficient cells 
A. Robust Z score distribution of siRNAs targeting 178 tumour suppressor genes in 
ATM isogenic cell line models.  
B. Colony formation assay demonstrating synthetic lethality in the ATM fibroblast 
isogenic model system, transfected with 2 independent siRNAs specifically targeting 
PTEN (Qiagen). Survival fractions were calculated based on scrambled control, 
transfected cells. (* p = <0.05 Students-t test). (Validation of the siRNA targeting 
PTEN, Supplementary Fig. 1B). 
C. Colony formation assay demonstrating synthetic lethality in the HCT116 and PC3 
PTEN isogenic model systems, transfected with 2 siRNAs specifically targeting ATM 
(Qiagen) (Validation of the siRNA targeting ATM, Supplementary Fig. 1B) (* p = 
<0.05 Students-t test). PTEN wild-type cells: HCT WT and PC3+PTEN and PTEN 
deficient cells, HCT KO22 and PC3-PTEN. 
D. Colony formation assay demonstrating synthetic lethality in the HCT116 and PC3 
PTEN isogenic model systems, treated with increasing concentrations of the ATM 
inhibitor KU-55933. Survival fractions were calculated based on DMSO treated cells. 
Solid lines indicate PTEN wild-type cells and broken lines indicate PTEN-deficient 
cells. 
 
Figure 2: PTEN-deficient cells have elevated levels of ROS, DNA damage and 
activation of ATM 
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A. Oxidative stress assay demonstrating increased basal reactive oxygen species in 
(i) HCT116 (ii) PC3 PTEN isogenic cells. ** p= <0.01 and *** p= <0.001 Students-t 
test. 
B. Increase d γ-H2AX, phospho-ATM serine 1981 and phospho-CHK2 threonine 68 
levels in PTEN HCT116 (KO22) and PC3 (PC3-PTEN) deficient cells compared to 
wild-type counter-parts. Total ATM and CHK2 were used as loading controls. 
C. Reversal of increased γ-H2AX and phospho-ATM levels in PTEN-deficient 
HCT116 and PC3 cells treated with 100μM β-carotene or 10μM NAC. β-Actin and 
total ATM were used as loading controls.  
D. Colony formation assay of PTEN wild-type and deficient HCT116 cells treated with 
10μM KU-55933 in the absence and presence of 100μM β-carotene or 10μM NAC. * 
p= <0.05 Students-t test. 
 
Figure 3: Acute inhibition of ATM in PTEN null cells results in cell cycle arrest, 
chromosome aberrations and apoptosis 
A. G2/M arrest in PTEN-deficient HCT116 cells treated with 10µM KU-55933 for 72 
hours (* p = <0.05).  
B. M phase arrest in PTEN-deficient HCT116 cells treated with 10µM KU-55933 for 
72 hours (* p = <0.05). % increase from DMSO treated cells. 
C. Increased chromosome breaks and aberrations in PTEN-deficient HCT116 cells 
after treatment with 10µM KU-55933 for 72 hours (* p = <0.05).  
D. HCT116 wild-type and KO22 cells were treated with 10µM KU-55933 for 96 hours 
and analysed for caspase 3/7 activation (* p = <0.05). % increase from DMSO 
treated cells. 
 
Figure 4: In vivo efficacy of ATM inhibition in PTEN-deficient xenografts 
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A. Relative tumour volume curves for PTEN+/+ untreated control (●), PTEN-/- 
untreated control (●), KU-60019 treated PTEN+/+ (■) and PTEN-/- (■) PC-3 xenografts. 
Mean relative tumour volume is plotted against time from initial treatment. Target 
tumour volume was 400mm3 i.e. 4-fold increase in size from initial treatment. T-tests 
were performed at 30 days. Each treatment group contained 4 animals.  
B. Box plot of mean relative change in body weight during treatments. 
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Gene Function Average Z Score 
BRIP1 (FANCJ) DNA repair -10.029 
CDKN2C G1/S checkpoint -8.373 
PTEN Negative regulator PI3K -6.256 
STEAP4 Immunity and response to oxidative stress -5.322 
NKTR Immunity -4.452 
CASP8 Apoptosis -2.541 
TP53 G1/S checkpoint -2.459 
FANCG DNA repair -2.316 
CAV1 Cell cycle progression/RAS signalling -2.023 
Table 1. siRNA hits 
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Figure 2. PTEN null cells have elevated levels of ROS, DNA damage and activated 
ATM kinase which is rescued by treatment with anti-oxidants 
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Figure 3. Acute inhibition of ATM in PTEN null cells results in cell cycle arrest, 
chromosome aberrations  and apoptosis 
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Figure 4. In vivo efficacy of ATM inhibition with PTEN loss  
                         COMPARISON T-Test 
PTEN WT VS DEFICIENT (VEHICLE) 0.3218 
PTEN WT VEHICLE VS PTEN WT KU60019 0.1213 
PTEN DEFICIENT VEHICLE VS KU60019 0.0004 
PTEN WT VS  PTEN DEFICIENT (KU60019) 0.006 
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Supplementary Information 
Supplementary Figure legends 
Figure 1: ATM is a potential drug target for PTEN-deficient cells 
A.i. Stable expression of recombinant FLAG tagged-ATM or empty vector in the ATM 
deficient fibroblast cell line AT22IJE-T, and correlation with phosphorylation of CHK2 
on threonine 68 in the absence/presence of 6 Gy IR as indicated. Total CHK2 and 
gamma-tubulin were used as loading controls. 
ii. Epression of PTEN in the HCT116 cell line model in wild-type cells and loss of 
expression in a knock-out clone (KO22). The inverse correlation of pAKT serine 473 
is also shown. 
iii. Inducible expression of wild-type PTEN in the PC3 prostate cancer cell line after 
72H tetracycline addition. The inverse correlation of pAKT serine 473 is also shown. 
B.i. Knockdown of PTEN using 2 independent siRNAs. Untransfected and Scrambled 
transfected cells were used as controls. Beta-tubulin was used as a loading control. 
ii. Knockdown of ATM using 2 independent siRNAs. Untransfected and Scrambled 
transfected cells were used as controls. Vinculin was used as a loading control. 
C.i. Western blot analysis of PTEN expression in a panel of cancer and normal cell 
lines. 
ii. Colony formation assay showing sensitivity to the ATM inhibitor KU-55933 in a 
panel of cancer and normal cell lines. 
 
Figure 2: The synthetic lethality with PTEN loss and ATM inhibition is 
independent of AKT function 
A. Phospho-AKT serine473 expression in PTEN deficient KO22 cells treated with (i) 
1 and 10µM KU-55933 and (ii) 1, 5 and 10µM MK2206 (AKT inhibitor) for 48 hours.  
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B. Colony formation assay of PTEN wild-type and deficient HCT116 cells treated with 
5µM MK2206 and 10µM KU-55933 and then in combination. Survival fraction was 
normalized to DMSO.  
 
Figure 3: The synthetic lethality with PTEN loss and ATM inhibition is 
independent of RAD51 function 
A. RAD51 expression in the PTEN isogenic cell lines (i) and across a panel of PTEN-
deficient and wild-type cell lines (ii). 
B. Increased RAD51 focus formation in HCT116 PTEN wild-type cells with and 
without HU treatment. Data is representative of 3 independent experiments. * 
p=<0.05 Students-t test. 
C. (i) Colony formation assay of PTEN wild-type and deficient HCT116 and PC3 cells 
transfected with RAD51 siRNA. Survival fraction was normalized to scrambled 
control. (ii) Western blotting analysis of the RAD51 siRNA was performed in the 
HCT116 wild-type cells using 10nM siRNA and beta-actin as a loading control. 
D. Increased gamma-H2AX foci formation in HCT116 PTEN-deficient cells. Positive 
cells were counted as cells with more than five foci in three independent 
experiments. 
 
Supplementary Figure 4: In vivo efficacy of ATM inhibition with PTEN loss  
A. Western blot analysis of PTEN-inducible PC-3 tumour cells exposed to 2µg/ml of 
doxycycline or tetracycline in vitro.  
B. Western blot analysis of PTEN-inducible PC-3 subcutaneous tumours resected 
from SCID mice at specific time points (0-28 days) following initial oral gavage 
administration of doxycycline [16mg/kg].  
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C. Tumour volumes (mm3) were measured to assess the effect doxycycline-induction 
of tumour suppressor PTEN had on tumour growth (●) (vs. control (■)). Each 
experimental condition consisted of 4 mice. Error bars represent ± standard error of 
the mean (SEM). 
D. Co-staining of resected xenograft tumours by immunofluorescence for DAPI (Blue) 
and PTEN (Green).  
 
Materials and Methods 
Cell lines 
All cell lines were sourced from the American Tissue Culture Collection (ATCC). 
HCT116 cells lacking wild-type PTEN have been described previously and were 
licensed from Georgetown University (1). PTEN exon II was deleted from these cells 
by homolgous recombination using the cre-lox system resulting in complete loss of 
the PTEN protein in the KO22 cells (Supplementary Fig. 1a). The PC3-PTEN 
inducible cell lines were generated using the Virapower T-RexTM Lentiviral 
Expression System (Invitrogen) which resulted in Tetracycline-inducible expression 
of full-length PTEN in the PTEN mutant PC3 cell line (Supplementary Fig. 1a) (2). 
ATM deficient and complemented cells have previously been described (3). AT22IJE-
T, was derived from primary A-T fibroblasts and harbor a homozygous frameshift 
mutation at codon 762 of the ATM gene resulting in an unstable truncated protein. 
These cells were complemented with either the ATM full-length gene or an empty 
vector (Supplementary Fig. 1a) (3). All cell lines were validated by STR profiling. 
 
siRNA screening 
ATM isogenic cells were reverse transfected with the siRNA library (Qiagen) using 
Lipofectamine RNAiMax reagent as per manufacturer’s instructions (Life 
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Technologies) 2000 cells were transfected with 10nM siRNA. 24 hours later media 
was changed into normal growth media. 48 hours post-transfection cells were split at 
a ratio of 1:3 into new 96 well plates. The cells were allowed to grow for 10 days until 
~80% confluent. Cell viability was assayed using the Cell titre Glo assay (Promega). 
The sensitivity of the screen was monitored by (i) PLK1 siRNA causing a reduction in 
viability of more than 90% in both cell types, when compared to transfection with a 
non-targeting siRNA control (All-stars) (ii) Z-factor (4) for the cell lines was >0.5 (for 
ATM wild-type 0.543 and ATM deficient 0.580). The siRNA screen was performed 
once and the average robust z-scores of the 3 independent siRNAs targeting each 
gene was determined for each cell line.  
 
γH2AX focus formation 
Cells were fixed in 4% paraformaldehyde and permeablised with 0.5% Triton X-100/ 
PBS and stained with mouse monoclonal anti- γH2AX (Ser-139), 1:200 (20E3; Cell 
Signaling, UK). Positive cells were counted as cells with more than five foci in three 
independent experiments.  
 
In vivo study 
Subcutaneous xenograft tumours derived from the PC-3 PTEN tetracycline-inducible 
cell model were grown in male Fox Chase SCID (Severe Combined 
Immunodeficiency) mice (Charles River Laboratories, Oxford, UK.). PC-3 Cells were 
suspended fresh autoclaved PBS at 3 x 107 cells per ml and kept on ice until 
implantation. Implantation required mice to be anaesthetised. 100 µl of cell 
suspension (3 x 106 cells) was injected subcutaneously into the right flank of each 
mouse using a sterile syringe and 21G needle. Simultaneously, mice were 
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subcutaneously implanted with transponders for unique identification (Avid 
Identification Systems, California, USA). 
For in vivo studies, KU-60019 was dissolved in Hot Rod Chemistry (HRC) Rapid 
Formulation 6 (Pharmatek Laboratories, California, USA) to improve solubility and 
bioavailability. When tumour volumes reached 100 mm3, mice were randomly 
assigned into treatment groups. KU-60019 [100 mg/kg] and drug vehicle were 
administered orally once daily, for 5 consecutive days. PTEN was induced in the 
specified PTEN+/+ tumours by the oral gavage administration of 100 µl doxycycline 
[16 mg/kg] and repeated every 48 hours up to 14 days post-initial treatment. All 
experiments were carried out in accordance with the local ethical and Home Office 
Regulations (ASPA19/ project licence 2945) and designed in accordance with the 
Scientific Procedures Act (1986) and the 2010 Guidelines for the welfare and use of 
animals in cancer research (5). 
 
Measurement of Tumour Volumes 
4 animals were used per treatment group. This was calculated for effects which differ 
by 20%, with a standard deviation of 10% and results in an 80% power to detect the 
effect with statistical significance (p < 0.05, two-tailed t-test) (6). Xenograft tumour 
generation was monitored from 1 week following injection onwards using volumetric 
measurements with external callipers. Measurements of tumour volume and body 
weight took place every 3 days. In order to assess tumour volume by external 
callipers, the greatest longitudinal diameter (length), the greatest transverse diameter 
(width) and the greatest vertical diameter (breadth) were measured and the 
geometric mean diameter (GMD) calculated. Tumour volume estimates could then be 
derived. 
ܩܯܦ =  ∛(ܮ × ܤ × ܪ) 
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ݎ = ܩܯܦ2  
ݒ݋݈ݑ݉݁ = ൬43൰ × (ߨ × ݎ
ଷ) 
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Supplementary Table 1: siRNA target genes (tumour suppressor genes or genes 
whose loss has been implicated in cancer development) 
Entrez Gene Id NCBI gene symbol 
324 APC 
613 BCR 
857 CAV1 
1031 CDKN2C 
1869 E2F1 
2297 FOXD1 
3055 HCK 
4163 MCC 
4763 NF1 
5728 PTEN 
472 ATM 
641 BLM 
858 CAV2 
1033 CDKN3 
1958 EGR1 
2313 FLI1 
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3090 HIC1 
4221 MEN1 
4771 NF2 
5888 RAD51 
545 ATR 
672 BRCA1 
999 CDH1 
1111 CHEK1 
2067 ERCC1 
2353 FOS 
3091 HIF1A 
4255 MGMT 
4820 NKTR 
5925 RB1 
580 BARD1 
675 BRCA2 
1026 CDKN1A 
1540 CYLD 
2177 FANCD2 
2355 FOSL2 
3726 JUNB 
4292 MLH1 
4978 OPCML 
5931 RBBP7 
581 BAX 
694 BTG1 
1027 CDKN1B 
1612 DAPK1 
2189 FANCG 
2547 XRCC6 
3727 JUND 
4436 MSH2 
5157 PDGFRL 
5933 RBL1 
595 CCND1 
754 PTTG1IP 
1028 CDKN1C 
1630 DCC 
2195 FAT1 
2873 GPS1 
3732 CD82 
4481 MSR1 
5245 PHB 
5934 RBL2 
596 BCL2 
836 CASP3 
1029 CDKN2A 
1647 GADD45A 
2196 FAT2 
2874 GPS2 
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3814 KISS1 
4616 GADD45B 
5591 PRKDC 
6041 RNASEL 
602 BCL3 
841 CASP8 
1030 CDKN2B 
1755 DMBT1 
2241 FER 
2956 MSH6 
4089 SMAD4 
4681 NBL1 
5727 PTCH1 
6251 RSU1 
6400 SEL1L 
7048 TGFBR2 
7411 VBP1 
8061 FOSL1 
8797 TNFRSF10A 
9821 RB1CC1 
10744 PTTG2 
11319 ECD 
26524 LATS2 
51684 SUFU 
6648 SOD2 
7157 TP53 
7428 VHL 
8314 BAP1 
8844 KSR1 
9940 DLEC1 
10912 GADD45G 
11334 TUSC2 
27156 RTDR1 
51741 WWOX 
6764 ST5 
7158 TP53BP1 
7490 WT1 
8438 RAD54L 
9113 LATS1 
10078 TSSC4 
11068 CYB561D2 
21933 Tnfrsf10b 
28316 CDH20 
51752 ERAP1 
6767 ST13 
7159 TP53BP2 
7507 XPA 
8535 CBX4 
9232 PTTG1 
10168 ZNF197 
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11144 DMC1 
22908 SACM1L 
28513 CDH19 
54879 ST7L 
6768 ST14 
7161 TP73 
7520 XRCC5 
8555 CDC14B 
9537 TP53I11 
10256 CNKSR1 
11145 PLA2G16 
23221 RHOBTB2 
29997 GLTSCR2 
54979 HRASLS2 
6794 STK11 
7184 HSP90B1 
7873 ARMET 
8556 CDC14A 
9540 TP53I3 
10263 CDK2AP2 
11178 LZTS1 
25855 BRMS1 
29998 GLTSCR1 
55294 FBXW7 
6868 ADAM17 
7251 TSG101 
7982 ST7 
8626 TP63 
9589 WTAP 
10395 DLC1 
11186 RASSF1 
25900 IFFO1 
51213 LUZP4 
57110 HRASLS 
6886 TAL1 
7260 TSSC1 
7991 TUSC3 
8743 TNFSF10 
9705 ST18 
10641 TUSC4 
11200 CHEK2 
26255 PTTG3 
51352 WIT1 
57509 MTUS1 
57786 RBAK 
84445 LZTS2 
286827 TRIM59 
64061 TSPYL2 
84955 NUDCD1 
338440 ANO9 
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79577 CDC73 
94241 TP53INP1 
79689 STEAP4 
120114 FAT3 
79728 PALB2 
124641 OVCA2 
83937 RASSF4 
129025 ZNF280A 
83990 BRIP1 
140883 ZNF280B 
84312 BRMS1L 
283455 KSR2 
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Supp Figure 3. The synthetic lethality with PTEN loss and ATM inhibition 
is independent of RAD51 function 
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Supplementary Figure 4: In vivo efficacy of ATM inhibition in PTEN deficient 
xenografts  
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